Navigation Links
Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009

ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Penny Heaton, V.P., and Chief Medical Officer, will be presenting at the Phacilitate Vaccine Forum Washington 2009 conference on January 26, 2009 at the Grand Hyatt in Washington D.C. Dr. Heaton is participating in the Focus Session 'What benefits are single-use technologies and other novel vaccine manufacturing solutions providing in practice' and will be speaking to the Case Study: Virus-Like Particle (VLP) based vaccines for pandemic and seasonal influenza. Slides from the presentation will be posted on the Novavax website at

There are several reasons for utilizing virus-like particle technology as a vaccine platform. Recombinant technology permits tailoring of vaccines to contain only those proteins that are immunologically important for protection and structurally important for optimizing expression and yields. In addition, preclinical and clinical data have shown that VLPs activate multiple arms of the immune system, inducing robust humoral and cell-mediated immunity, which permits vaccine development for a wide range of disease targets. Further, VLPs may be more cost effective to produce because vaccines against different disease targets may be manufactured utilizing the same process and facility. Dr. Heaton's presentation will discuss these advantages, with a specific focus on the potential immunologic and manufacturing benefits of Novavax's pandemic and seasonal influenza VLP vaccines.


Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Penny Heaton

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
2. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
3. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
4. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
5. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
6. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
7. Novavax CEO to Present at BIO Investor Forum 2008
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
10. Novavax Announces Closing of $18 Million Registered Direct Offering
11. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Twist ... announced that Emily Leproust, Ph.D., Twist Bioscience chief ... Jaffray Healthcare Conference on December 1, 2015 at ... Hotel in New York City. --> ... . Twist Bioscience is on Twitter. ...
(Date:11/24/2015)... -- Capricor Therapeutics, Inc. (NASDAQ: CAPR ... and commercialization of first-in-class therapeutics, today announced that ... to present at the 2015 Piper Jaffray Healthcare Conference ... The Lotte New York Palace Hotel in ... --> . --> ...
(Date:11/24/2015)... According to two new studies, fewer men are having PSA ... doctors, scientists, and public health experts have been pushing for ... being done, will there be more men dying of ... "Despite the efforts made in regards to early detection for ... of death in men, killing approximately 27,500 men this year. ...
(Date:11/23/2015)... ... 23, 2015 , ... Noblis, Inc., a leading provider of science, technology, and ... Geospatial Intelligence Agency (NGA), has joined the Noblis NSP team as President of the ... intelligence community and the private sector,” said L. Roger Mason, Jr., Ph.D. , ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
Breaking Biology News(10 mins):